bves Antibody

What is BVES and why is it important in research?

BVES (blood vessel/epicardial substance), also known as POPDC1 (Popeye domain-containing protein 1), is an evolutionarily conserved transmembrane protein first identified in 1999 by two independent laboratories screening for genes highly expressed in the developing heart . With a molecular weight of approximately 41 kDa, BVES is postulated to play critical roles in cell-cell interaction and adhesion . The protein is important for establishing and maintaining cell integrity, regulating tight junction formation, modulating vesicular transport, and influencing cell shape and movement through Rho-family GTPase activity regulation . BVES has emerged as significant in multiple research areas including cardiovascular development, epithelial biology, and potential cancer research applications .

Antibody studies have revealed that BVES expression is more widespread than initially determined by mRNA studies alone. Using various monoclonal and polyclonal antibodies, BVES has been detected in:

• Myocytes of the developing heart throughout development

• Skeletal and smooth muscle cells, including coronary smooth muscle

• Specific epithelial derivatives of all three germ layers (ectoderm, mesoderm, endoderm)

• Epithelial components of the digestive tract and respiratory system

• Cell lines derived from rat epithelial epicardium (EMC), differentiated mouse skeletal myoblasts (C2C12), human corneal epithelium (HCE), and canine kidney epithelial cells (MDCK)

Notably, there has been discrepancy between mRNA expression analysis (showing primarily muscle expression) and immunochemical studies (showing expression in various epithelia), possibly due to low levels of BVES message in non-muscle cell types .

What are the optimal protocols for using BVES antibodies in immunofluorescence studies?

Based on published methodologies for the SB monoclonal antibody series, the following protocol has been established for BVES immunofluorescence :

• Fixation: Fix tissue sections or cultured cells for 10 minutes in cold 70% methanol

• Washing: Wash three times with PBS

• Permeabilization: Permeabilize with 0.25% Triton X-100 in PBS for 10 minutes

• Washing: Wash with PBS three times

• Blocking: Block non-specific binding by incubation with 2% bovine serum albumin in PBS for one hour at room temperature

• Primary antibody: Apply BVES antibodies (e.g., ascites fluids at 1:2,000 dilutions) for 1-16 hours at room temperature

• Secondary antibody: Add Alexa-conjugated secondary antibodies for one hour at room temperature

• Visualization: Counterstain as needed (e.g., DAPI for nuclei) and perform standard washing procedures

This methodology has been validated for detecting BVES in both tissue sections and cultured cells with minimal background and high specificity .

How can researchers validate the specificity of BVES antibodies?

Specificity validation is critical for BVES antibodies, especially considering the existence of related Popdc family members. A comprehensive validation approach should include :

• Transfection studies: Transfect COS-7 cells with c-myc-tagged BVES expression constructs, followed by co-immunofluorescence using anti-c-myc and putative BVES antibodies to confirm co-localization

• Cross-reactivity testing: Test antibodies against other Popdc family members (Popdc2, Popdc3) and unrelated proteins to ensure specificity:

  • Transfect cells with c-myc tagged Bves, Popdc2, and Popdc3

  • Perform immunostaining with both anti-c-myc and BVES antibodies

  • Verify selective reactivity with BVES only

• Immunoblotting: Generate GST-fusion proteins of each BVES family member and perform Western blotting to confirm antibody specificity

• Affinity chromatography: Test antibody binding to purified GST-BVES using Sepharose-bound antibodies

In published studies, properly validated BVES antibodies like the SB series demonstrated specific binding to BVES without cross-reactivity to Popdc2 or Popdc3 .

How can BVES antibodies be used to investigate subcellular localization and trafficking dynamics?

BVES demonstrates a dynamic subcellular distribution pattern during cell-cell junction formation, making it an excellent target for studying epithelial polarization and junction assembly :

• Sequential staining approach: Use BVES antibodies in conjunction with markers for various cellular compartments (ZO-1 for tight junctions, E-cadherin for adherens junctions) at different time points during junction formation

• Time-course experiments: Track BVES localization during:

  • Cell polarization: When cells are not polarized or in contact, BVES is observed intracellularly

  • Initial adhesion: BVES is among the first proteins transported to the membrane, preceding classical junctional markers

  • Junction maturation: BVES localizes to points of cell-cell contact

  • Long-term confluent cultures: BVES localizes almost exclusively at the cell surface

• Z-stack confocal analysis: Use confocal microscopy with BVES antibodies to analyze the lateral distribution along the cell membrane, which reveals varying staining patterns depending on the specific antibody used

• Live-cell imaging: Apply minimally invasive antibodies against the extracellular domain of BVES (when available) to track real-time changes during junction formation

These approaches have revealed that BVES displays a lateral distribution in polarized epithelial cells and co-localizes with tight junction proteins like ZO-1 and Occludin, as well as the adherens junction protein E-cadherin .

How have discrepancies between different BVES antibodies been reconciled in research?

A notable research challenge has been the discrepancy in staining patterns between different BVES antibodies, even those raised against the same epitope . Researchers have addressed this through several approaches:

• Comparative analysis: Systematic side-by-side testing of monoclonal and polyclonal antibodies on the same samples to document differences:

  • Polyclonal B846 antibody: More restricted to tight junction regions

  • SB monoclonal series: Broader distribution along the lateral membrane

• Multiple antibody validation: Confirmation of results using antibodies raised against different epitopes

• Cross-species verification: Testing antibody reactivity across species (human, mouse, chicken, Xenopus) to identify conserved staining patterns

• Correlation with other techniques: Integration of antibody results with mRNA expression data and genetic approaches (e.g., lacZ knock-in mice)

The research community has concluded that differences may reflect detection of different isoforms, post-translational modifications, or conformational states of BVES in different cellular contexts .

What evidence supports the use of BVES antibodies in cancer research?

Recent studies have implicated BVES in cancer biology, suggesting valuable applications for BVES antibodies in this field :

• Methylation studies: Feng et al. reported BVES DNA methylation in non-small cell lung (NSCL) cancer, with hypermethylation in 24% of cases and 'some' methylation in 35% of cases

• Diagnostic marker potential: BVES was part of a three-gene panel that identified 51% of cancerous tissue (and only 2% of non-cancerous tissue)

• Tumor suppressor investigation: BVES functions in cell adhesion suggest potential tumor suppressor activity that can be explored using antibodies to:

  • Compare BVES expression levels in normal versus tumor tissues

  • Investigate changes in subcellular localization during malignant transformation

  • Examine correlation between BVES expression patterns and tumor progression

• Metastasis research: Since BVES regulates cell adhesion and migration, antibodies can be employed to study its role in metastatic processes

These applications position BVES antibodies as valuable tools in investigating the protein's potential role in cancer biology beyond its established functions in epithelial and muscle tissues .

How have BVES antibodies been used in functional studies affecting biological systems?

BVES antibodies have moved beyond purely descriptive studies to functional applications, particularly in ocular research :

Armstrong et al. demonstrated that antibodies targeting the extracellular domain of BVES can influence intraocular pressure (IOP) when injected intracamerally in rat models:

• Differential effects based on targeting domain:

  • Antibodies targeting the extracellular domain significantly lowered IOP by 4-5 mm Hg for 4 days in rats with normal IOP

  • Intracellular domain antibodies showed no effect on IOP

  • In elevated IOP models (using polystyrene microbead injections), extracellular antibodies resulted in a negative cumulative pressure effect for up to 5 days

• Mechanistic hypothesis: Since BVES regulates tight junction formation and tight junctions influence aqueous outflow resistance, disruption of BVES function in the anterior chamber can alter IOP

• Verification methods: Immunofluorescent staining of the anterior segment was performed at various time points to examine spatial and temporal distribution of injected BVES antibodies

This research represents an important transition from using BVES antibodies merely as detection tools to employing them as functional modulators in biological systems, potentially opening new therapeutic avenues .

What challenges exist in interpreting contradictory BVES expression data from antibody versus mRNA studies?

A significant challenge in BVES research has been reconciling the discrepancy between mRNA expression studies and antibody-based protein detection :

• Nature of discrepancy:

  • mRNA studies (in situ hybridization, lacZ knock-in): Show expression primarily in cardiac and skeletal muscle, with little epithelial expression

  • Antibody studies: Reveal BVES in muscle and various epithelial tissues

• Potential explanations:

  • Low message levels in non-muscle cell types may make mRNA detection difficult

  • Post-transcriptional regulation might result in higher protein than mRNA levels

  • Different sensitivity thresholds between techniques

  • Potential cross-reactivity of antibodies (though careful validation mitigates this concern)

• Research approaches to address discrepancies:

  • Use of multiple antibodies generated by different laboratories

  • Correlation with functional studies

  • Employment of genetic approaches (e.g., conditional knockout models)

  • Integration of cell line studies with consistent cell identities

Researchers are advised to interpret negative results cautiously, as many factors can affect assay outcomes independent of actual protein presence .

What emerging applications exist for BVES antibodies in developmental biology?

Based on the characterization of BVES expression across various tissues during development, several promising research directions for BVES antibodies include :

• Epithelial-mesenchymal transition (EMT) studies: Track BVES distribution during developmental EMT processes, such as in neural crest migration, epicardial cell invasion, and gastrulation

• Organ-specific developmental research:

  • Cardiovascular development: Further exploration of BVES in heart development and coronary vessel formation

  • Respiratory system: Investigation of differential expression in trachea versus smaller airways

  • Digestive tract: Examination of BVES roles in gut epithelial development

• Lineage tracing: Use of BVES antibodies in conjunction with other markers to track cell fate decisions and differentiation processes

• Evolutionary developmental biology: Comparative analysis of BVES expression across species can reveal evolutionary conservation of function

Investigators have noted that understanding the broad expression pattern of BVES across muscle and epithelial derivatives suggests its function is likely general in nature, affecting fundamental cellular processes during development .

How can researchers design experiments to better understand BVES interaction partners using antibodies?

To advance understanding of BVES molecular mechanisms, antibody-based approaches to identify and characterize interaction partners are crucial :

• Co-immunoprecipitation strategies:

  • Use BVES antibodies to pull down protein complexes from various tissues and cell types

  • Combine with mass spectrometry to identify novel binding partners

  • Confirm interactions using reverse co-immunoprecipitation with antibodies against putative partners

• Proximity labeling approaches:

  • Modify BVES antibodies for proximity labeling techniques (BioID, APEX)

  • Identify proteins in close proximity to BVES in living cells

  • Compare interactomes across different cell types and developmental stages

• Investigation of known partners:

  • Examine co-localization with GEFT (a RhoA GEF that interacts with BVES)

  • Study VAMP3 interactions to understand vesicular transport roles

  • Explore cAMP binding through functional antibody studies

• Domain-specific antibody studies:

  • Generate antibodies against specific BVES domains to disrupt particular interactions

  • Use domain-specific antibodies to map interaction surfaces

These approaches would address the current knowledge gap regarding BVES's molecular function and integration into established cell biological pathways .